CD274 and neoplasm: These included OX40 agonism mediated by PD-L1 on tumor or immune cells to enhance the T-cell co-stimulation, directed intratumoral targeting, and enhanced intratumoral T-cell co-stimulation, and, finally, ADCC-mediated depletion of PD-L1+ tumor cells.